A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

Grant

Awarded By

Total Award Amount

  • 593008.00

    • Direct Costs

  • 456160.00

    • Sponsor Award Id

    • Contributor

  • Racquel Innis-Shelton M.D.   Investigator